Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $52.44 down -1.41% from its previous closing price of $53.19. In other words, the price has decreased by -$1.41 from its previous closing price. On the day, 1.38 million shares were traded. CRSP stock price reached its highest trading level at $53.45 during the session, while it also had its lowest trading level at $52.35.
Ratios:
For a deeper understanding of CRISPR Therapeutics AG’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.22 and its Current Ratio is at 16.22. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In the most recent recommendation for this company, JP Morgan on September 18, 2025, initiated with a Overweight rating and assigned the stock a target price of $70.
On February 14, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line and also upped its target price recommendation from $60 to $99.
TD Cowen Upgraded its Sell to Hold on February 12, 2025, while the target price for the stock was maintained at $35.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 22 ’25 when Prasad Raju sold 10,000 shares for $55.95 per share. The transaction valued at 559,549 led to the insider holds 6,767 shares of the business.
RAJU PRASAD bought 10,000 shares of CRSP for $559,548 on Dec 22 ’25. On Oct 17 ’25, another insider, Kulkarni Samarth, who serves as the Chief Executive Officer of the company, sold 50,895 shares for $67.91 each. As a result, the insider received 3,456,279 and left with 254,201 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 4997543936 and an Enterprise Value of 3292858112. For the stock, the TTM Price-to-Sale (P/S) ratio is 130.35 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 85.892 whereas that against EBITDA is -7.166.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.70, which has changed by 0.27840078 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $78.48, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is -7.66%, while the 200-Day Moving Average is calculated to be 1.79%.
Shares Statistics:
For the past three months, CRSP has traded an average of 2.30M shares per day and 1533170 over the past ten days. A total of 93.87M shares are outstanding, with a floating share count of 91.55M. Insiders hold about 3.94% of the company’s shares, while institutions hold 71.43% stake in the company. Shares short for CRSP as of 1765756800 were 21863725 with a Short Ratio of 9.49, compared to 1763078400 on 23186755. Therefore, it implies a Short% of Shares Outstanding of 21863725 and a Short% of Float of 25.759999999999998.
Earnings Estimates
The stock of CRISPR Therapeutics AG (CRSP) is currently in the spotlight, with 17.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$1.09, with high estimates of -$0.87 and low estimates of -$1.25.
Analysts are recommending an EPS of between -$4.97 and -$6.86 for the fiscal current year, implying an average EPS of -$6.2. EPS for the following year is -$4.46, with 19.0 analysts recommending between -$2.0 and -$6.22.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $27.6M, while the lowest revenue estimate was $2.6M, resulting in an average revenue estimate of $6.22M. In the same quarter a year ago, actual revenue was $37.31M
